Combined Treatment with Micro-Focused Ultrasound with Visualization and Intradermal Incobotulinumtoxin-A for Enlarged Facial Pores: A Retrospective Study in Asians

Figures & data

Figure 1 Protocol of the combined treatment with micro-focused ultrasound with visualization (MFU-V) and intradermal incobotulinumtoxin-A (INCO). Both anterior cheeks were divided into four square areas of 2.5×2.5 cm². First, MFU-V treatment was administered by 25 treatment lines per square using a 10-MHz/1.5 mm transducer. Then, 2.5 U of diluted INCO was intradermally injected in each square. In total, 100 lines of MFU-V and 10 U of INCO were administered on each cheek.

Table 1 Changes in Facial Pore Count and Density at Baseline and 1, 4, 12, and 24 Weeks After Combined Treatment with MFU-V and Intradermal INCO

	Baseline	Follow-Up After Treatment
		Week 1	Week 4	Week 12	Week 24
Pore count	1130.6 ± 288.4	870.2 ± 236.2	673.3 ± 209.2	529.5 ± 190.0	429.3 ± 128.5
Pore density (%)	29.7 ± 8.8	23.1 ± 8.1	17.8 ± 6.9	14.0 ± 5.7	11.1 ± 3.5

Table 2 Changes in Physician and Patient Global Aesthetic Improvement Scale Scores at Baseline and 1, 4, 12, and 24 Weeks After Combined Treatment with MFU-V and Intradermal INCO

		Follow-Up After Treatment
		Week 1	Week 4	Week 12	Week 24
Physician Global Aesthetic Improvement Scale	0 (worsened)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	1 (no change)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	2 (improved)	0 (0%)	13 (65%)	7 (35%)	4 (20%)
	3 (much improved)	8 (40%)	6 (30%)	13 (65%)	12 (60%)
	4 (very much improved)	12 (60%)	1 (5%)	0 (0%)	4 (20%)
Patient Global Aesthetic Improvement Scale	0 (worsened)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	1 (no change)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	2 (improved)	1 (5%)	9 (45%)	2 (10%)	1 (5%)
	3 (much improved)	9 (45%)	10 (50%)	16 (80%)	12 (60%)
	4 (very much improved)	10 (50%)	1 (5%)	2 (10%)	7 (35%)

Figure 2 Facial pore count and density at baseline and each follow-up visit after combined treatment with MFU-V and intradermal INCO.

Figure 3 Clinical photographs of a patient before and after combined treatment with MFU-V and intradermal INCO. Compared to the (A) baseline (pore count, 1353; pore density, 39.71%), the countable facial pores decreased at (B) 1 week (pore count, 1023; pore density, 29.62%), (C) 4 weeks (pore count, 558; pore density, 16.24%), (D) 12 weeks (pore count, 448; pore density, 13.02%), and (E) 24 weeks (pore count, 308; pore density, 8.94%) after the combined treatment.

Figure 4 Trends in physician and patient Global Aesthetic Improvement Scale scores before and after combined treatment with MFU-V and intradermal INCO.